ClinicalTrials.gg
Not yet recruitingNCT07849595REMAP-BP-HIVUpdated Sep 30, 2026

Monitoring Blood Pressure at Home and Pharmacy Telehealth Among People Living With HIV

An interventional study of Remote Blood Pressure Monitoring + Telehealth in Hypertension and Blood Pressure Monitoring, sponsored by University of Alabama at Birmingham. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
572
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypertension by University of Alabama at Birmingham — 13 open to participants now, 16 under way, 1 of them phase 3. Hypertension · University of Alabama at Birmingham.

Planned enrollment
4th of 38
572 · median 71
Started
2027
with 1 other
No phase
29 of 44
11 open now
Primary completion
2031-02
later than 15 of 15 live
Registered
44th of 44
by date

Among the 44 studies in Hypertension by University of Alabama at Birmingham, this one is the 4th largest by planned enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2027, is one of 29 with no phase, reaches primary completion later than 15 of the 15 other live ones, and was the 44th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

13 of the 44 studies in Hypertension by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypertension by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

The overall goal of this project is to determine if measuring blood pressure at home and staying in contact with a team of pharmacists and physicians to manage participants' blood pressure is useful. The study will enroll 552 participants who are seen at the University of Alabama at Birmingham 1917 Dewberry Clinic and Vanderbilt Comprehensive Care Center. Half of the participants (276 patients) will be asked to measure blood pressure at home, and half of the participants (276 patients) will continue to receive usual care. Participants who measure blood pressure at home will also meet with a pharmacist weekly over the phone to discuss blood pressure readings and have blood pressure medications prescribed if needed. This program will last 6 months.

Read the detailed description

For all participants:1. Participants will receive information on the importance of measuring blood pressure and ways to improve blood pressure. 2. Participants will complete questionnaires describing current socioeconomic position, medical history and healthcare needs. 3. Participants will come in for three research clinic visits to get blood pressure measured 3 months after enrollment in this study, and 6 months after enrollment in this study.

For participants asked to measure blood pressure at home: 1. Measure blood pressure twice a day at home, following the instructions provided. The study will provide participants with the device and send text message reminders twice a week. Participants will return the device at study visit 3 months from now. 2. Following the instructions provided, participants will talk to a pharmacist over the phone weekly to discuss blood pressure and medications. All medication changes will be discussed with a collaborating physician. 3. Participants will complete questionnaires and interviews on satisfaction with the program.

03

Conditions studied

  • Hypertension
  • Blood Pressure Monitoring

Keywords

  • Cardiovascular diseases
  • Delivery of Health Care
  • Patient Care Management
  • Health Services Administration
  • Telemedicine
  • Vascular Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Ability to speak English
  • Seen at UAB's 1917 Dewberry Clinic or Vanderbilt's Comprehensive Care Clinic
  • Blood pressure at Clinic: Systolic BP ≥ 130 mmHg or Diastolic BP ≥ 80 mmHg
  • Have a cellphone with video capability

Exclusion criteria

Exclusion Criteria:

  • Systolic BP ≥ 160 mmHg or Diastolic BP ≥ 100 mmHg (i.e. severe range hypertension (HTN) by the 2025 American College of Cardiology/American Heart Association BP guidelines) as they typically are referred to immediate treatment intensification. Since the prevalence of severe HTN is low (i.e.\<5%) in the US population, exclusion of these individuals will have only a small effect on the study.)
  • Lack of willingness or inability to provide written
  • Individuals who work overnight or second shift
  • History of known major arrhythmias
  • Currently pregnant or breastfeeding
  • Arm circumference >50 cm. *The upper limit for the largest BP cuff for oscillometric BP devices is typically 50-52 cm; data from the National Health and Nutrition Examination Survey, 2011-2016 indicated that \<1% of US adults have an arm circumference >50 cm, so this will have minimal effect on our study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
572 participants (estimated)

Study arms

  • Active comparator
    Remote Blood Pressure Monitoring + Telehealth

    Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management

    Behavioral: Remote Blood Pressure Monitoring + Telehealth

  • No intervention
    Usual Care

    Participants receive usual care from providers to manage blood pressure

Interventions

  • BehavioralRemote Blood Pressure Monitoring + Telehealth

    Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management

    Also known as: Intervention group

06

What researchers measure

Primary outcomes

  1. Total Number of Enrolled Participants with Blood Pressure Control

    The number of enrolled participants with blood pressure control

    Time frame: Time Frame: 12 weeks (3 months) from randomization

Secondary outcomes

  1. Number of Participants in the Intervention with Patient-Reported Outcomes

    The number of participants with completed qualitative interviews and surveys regarding intervention adherence and satisfaction. The survey will assess intervention adherence and satisfaction using the following scales: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and the Feasibility of Intervention Measure (FIM). The AIM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better acceptability while the lower total score indicates worse acceptability. The IAM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better appropriateness while the lower total score indicates worse appropriateness. The FIM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better feasibility while the lower total score indicates worse feasibility.

    Time frame: Time Frame: 24 weeks (6 months) from randomization

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — While the investigators do not anticipate generating research tools, the investigators are committed to adhering to the National Institutes of Health (NIH) Research Tools Policy to ensure that any resources developed under this award are readily available to qualified researchers. If an NIH-defined research tool is developed, the investigators will collaborate with University of Alabama at Birmingham Commercialization and Licensing Office and all participating institutions to define ownership, protect intellectual property, and establish a dissemination strategy that ensures appropriate access and compliance with NIH guidelines.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Feb 2031, 48 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 48 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Feb 1, 2031
CompletionEst.
May 31, 2031
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849595
Responsible party
Lama Ghazi (Principle Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Sep 30, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Feb 1, 2031 (estimated)
Completion
May 31, 2031 (estimated)
Last update
Sep 30, 2026

Study contacts

Tammi Thomas
Contact
tammithomas@uabmc.edu
205-934-7839
Bernadette Johnson
Contact
bajohnson@uabmc.edu
205-934-7329
Lama Ghazi, MD, PhD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion